The therapy, described in a study published in Frontiers in Pharmacology, is built on Mycobacterium smegmatis, a fast-growing mycobacterial species that is inherently immunostimulatory but does not produce endotoxin. The researchers, led by Leilei Zhou, Zhaoye Qian, and Jipeng Wang of the Affiliated Huai’an No. 1 People’s Hospital of Nanjing Medical University, engineered the bacterium to secrete a bifunctional fusion protein: a single-chain variable fragment that blocks the PD-L1 immune checkpoint, fused to an interleukin-15 (IL-15) immunocytokine that includes the IL-15 receptor alpha sushi domain. The construct, dubbed Ms-PI15, is designed to combine checkpoint blockade with sustained local cytokine signaling that promotes the proliferation and activation of natural killer cells and CD8-positive T cells.

To test the approach, the team established a syngeneic model of malignant pleural effusion by injecting luciferase-expressing Lewis lung carcinoma cells directly into the left pleural cavity of C57BL/6 mice. Within days, the cells established pleural tumors, and by day 15 tumor cells were detectable in the pleural fluid, confirming that the model faithfully reproduced the human condition. Beginning on day five after tumor inoculation, mice received intrapleural injections of either phosphate-buffered saline, an empty-vector control bacterium, or Ms-PI15, repeated on days 10 and 15.

A dose-optimization experiment comparing 10 million and 100 million colony-forming units showed a clear dose-dependent effect. Mice receiving the higher dose displayed significantly reduced bioluminescent signal from the chest region on serial imaging, along with markedly smaller pleural tumor masses and reduced effusion volumes at the endpoint on day 21. Body weight remained stable across all groups throughout the observation period, an early indication that the treatment was well tolerated.

In the head-to-head efficacy experiment, the differences were striking. Tumor burden, quantified as total radiance efficiency over the chest, was significantly lower in the Ms-PI15 group from day 13 onward compared with both the saline and empty-vector controls. By day 21, tumor mass and effusion volume were both dramatically reduced, with p-values below 0.001 for tumor weight and below 0.0001 for effusion volume. Critically, the empty-vector bacterium performed no better than saline on any efficacy endpoint, demonstrating that the antitumor activity was specifically attributable to the PD-L1/IL-15 fusion protein rather than to the nonspecific immunostimulatory properties of the bacterial carrier itself.

Survival data reinforced the therapeutic signal. Median survival was 29 days in the saline group, 37 days in the empty-vector group, and 47 days in the Ms-PI15 group—a substantial extension that translated tumor suppression into a meaningful survival benefit in this aggressive model.

Understanding where the engineered bacteria go after injection was central to evaluating both mechanism and safety. The team labeled Ms-PI15 with the near-infrared fluorescent dye DiR and tracked its distribution over two weeks. Fluorescence accumulated predominantly in the pleural tumor region, peaking at 72 hours after administration and declining thereafter. Ex vivo imaging confirmed persistent signal at the tumor site and detectable fluorescence in the thoracic draining lymph nodes, suggesting that the bacteria, or antigens derived from them, migrate to or are transported by immune cells into the draining lymphatic system. Colony-forming unit counts from homogenized tissues corroborated the imaging: viable bacteria were abundant in tumor tissue and detectable in the draining nodes, but colonization of the heart, liver, spleen, lung, kidney, and blood was negligible or below the detection limit at every timepoint examined.

The immunological remodeling induced by Ms-PI15 was comprehensive. Flow cytometric analysis of the pleural tumor revealed a significant increase in the proportion of CD80-positive, CD86-positive mature myeloid dendritic cells among CD11c-positive cells, indicating enhanced antigen-presenting capacity. Macrophage polarization shifted markedly: the fraction of CD206-positive, M2-like immunosuppressive tumor-associated macrophages fell, while the proportion of CD86-positive, M1-like antitumor macrophages rose. Because tumor-associated macrophages are among the most abundant immune populations in malignant pleural effusion and actively promote tumor progression through pro-angiogenic signaling and suppression of cytotoxic lymphocytes, this repolarization represents a key mechanism of action.

Cytotoxic effector cells surged in parallel. The percentage of CD8-positive T cells in the tumor increased significantly, as did the fraction of NK1.1-positive, CD3-negative natural killer cells, and immunohistochemical staining of tumor sections independently confirmed the denser CD8-positive infiltration. The immune effects extended beyond the pleural cavity: CD8-positive T cells were also elevated in the spleen, and mature dendritic cells increased in the thoracic draining lymph nodes, pointing to systemic immune activation that the authors suggest may help guard against metastatic dissemination. Together, these changes describe a conversion of the immunosuppressive, cold pleural microenvironment into an immunologically active, hot one.

Biosafety findings were equally encouraging within the limits of the model. Histopathological examination of the heart, liver, spleen, lung, and kidney revealed normal architecture with no inflammation, necrosis, or other treatment-related abnormalities in any group. Serum biochemistry showed no significant differences in alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase, markers of hepatic function, nor in creatinine or urea, markers of renal function. The authors caution, however, that several questions remain before clinical translation: the Lewis lung carcinoma model represents a single tumor histology, the study used only male mice, some mechanistic experiments involved small cohorts, and long-term durability and immunological memory were not assessed. Larger animal studies and eventual clinical trials will be needed to determine whether intrapleural Ms-PI15 can reproduce these results in human patients with malignant pleural effusion.

Subject of Research: Intrapleural engineered Mycobacterium smegmatis immunotherapy for malignant pleural effusion in a mouse model

Article Title: Engineered Mycobacterium smegmatis-based intrapleural immunotherapy remodels the pleural immune microenvironment for malignant pleural effusion treatment

Article References: Zhou, L., Qian, Z., Yao, R., Chen, C., Pan, P., Guo, Z., Xu, Z., Mei, Y., & Wang, J. (2026). Engineered Mycobacterium smegmatis-based intrapleural immunotherapy remodels the pleural immune microenvironment for malignant pleural effusion treatment. Frontiers in Pharmacology, 17, Article 1972278. https://doi.org/10.3389/fphar.2026.1972278

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.1972278

Keywords: malignant pleural effusion, Mycobacterium smegmatis, in situ vaccine, PD-L1 blockade, interleukin-15, tumor microenvironment, dendritic cell maturation, macrophage polarization, CD8 T cells, NK cells, biodistribution, preclinical study

The platform, dubbed MnO2–R848@CM, was developed by Zhen Zhang of Sun Yat-sen University and colleagues working across institutions in China, including the Hong Kong University of Science and Technology (Guangzhou). Its architecture is deceptively simple. Ultrathin manganese dioxide (MnO2) nanosheets, roughly 84 nanometers across and a mere 1.5 nanometers thick, are first decorated with a polyethylene glycol derivative and then loaded with R848, a small-molecule agonist of Toll-like receptors 7 and 8 that acts as a potent immunological adjuvant. The drug loading reached an impressive 35.70 percent at an optimized feed ratio, held in place by a combination of Mn–N coordination bonds, pi–pi stacking interactions, and hydrophilic–hydrophobic forces mediated by the amino groups on the polymer coating.

The final and arguably most clever step is the camouflage. The researchers extracted membranes from 4T1 mouse breast cancer cells through repeated freeze–thaw cycles and co-extruded them with the drug-loaded nanosheets through a polycarbonate filter, producing particles cloaked in an authentic tumor-cell shell. Protein electrophoresis confirmed that the banding pattern of the coated particles matched that of the 4T1 membranes and was clearly distinct from membranes of 3T3 normal fibroblasts, which served as an irrelevant-membrane control. After coating, the particles grew to about 170 nanometers in lateral dimension and 15 nanometers in thickness, acquired a more negative surface charge that favors stable transport in blood, and remained well dispersed in simulated body fluids, with sizes consistently below 200 nanometers.

That disguise pays off in targeting. When the team labeled the particles with the fluorescent dye coumarin 6 and incubated them with 4T1 cancer cells, fluorescence inside the cells surged within the first hour and plateaued by about six hours, while normal 3T3 cells took up far less material. In living mice bearing 4T1 tumors, the membrane-coated particles accumulated in tumors progressively after intravenous injection, peaking at twelve hours — at which point tumor fluorescence was a striking 73.27-fold higher than in mice injected with free dye. Crucially, a biodistribution comparison showed that particles coated with 3T3 membranes showed no tumor enrichment, demonstrating that the homing is specifically mediated by the tumor-cell membrane’s own adhesion molecules rather than by any generic membrane effect.

Once the particles arrive, the tumor’s own chemistry triggers the payload. The tumor microenvironment is weakly acidic, and this acidity dissolves MnO2. In vitro release experiments showed that at pH 7.4, mimicking blood, less than 20 percent of R848 escaped over twelve hours, but at pH 5.0 roughly 45 percent was released within the first half hour and about 77 percent within three hours. This pH-gated behavior means the adjuvant stays locked up during circulation and is dumped only where it is needed — inside the tumor.

The therapeutic logic then unfolds in several reinforcing layers. MnO2 catalyzes the decomposition of hydrogen peroxide, which tumors overproduce, into oxygen, directly relieving the hypoxia that makes tumors resistant to radiation. Under X-ray irradiation, the released manganese ions amplify reactive oxygen species generation and deplete glutathione, the cell’s antioxidant shield. In cultured 4T1 cells treated with a 6 Gy radiation dose, the combination reduced viability by roughly 20 percent beyond radiation alone, produced the strongest signals of DNA double-strand breaks as measured by gamma-H2AX staining, and drove the highest levels of apoptosis. Immunohistochemical staining of treated tumors for HIF-1alpha, a master regulator of the hypoxic response, was markedly reduced in mice receiving the full combination, confirming that hypoxia relief operates in vivo as well.

Radiation’s second, subtler gift is immunogenic cell death, in which dying tumor cells hoist danger flags — calreticulin on their surface, and ATP and HMGB1 released outside — that alert the immune system. The combination of MnO2–R848@CM and radiation produced the greatest calreticulin translocation, the lowest residual nuclear HMGB1, and the highest ATP release in cultured cells. These damage signals then act on dendritic cells, the sentinels of adaptive immunity. In mouse bone-marrow-derived dendritic cells, MnO2 alone raised maturation marker expression (CD80/CD86) from 59.2 to 76.2 percent, R848 alone to 78.0 percent, and the combination performed even better, while also driving robust secretion of the inflammatory cytokine TNF-alpha. In a Transwell system separating irradiated tumor cells from dendritic cells, the full combination pushed dendritic cell maturation to 77.5 percent, far above radiation alone. Mechanistically, manganese ions are known to accelerate the DNA-sensing enzyme cGAS and strengthen the binding of its product, cGAMP, to the STING adaptor, triggering type I interferon production — a pathway the team confirmed was activated in the treated dendritic cells.

The in vivo results were dramatic. In 4T1 tumor-bearing mice given a single injection followed by three radiation sessions, the membrane-coated platform combined with radiation achieved a tumor growth inhibition rate of 92.30 percent, with some mice showing complete tumor ablation. Tumor sections revealed the most extensive necrosis, the most apoptotic cells, and the strongest suppression of the proliferation marker Ki67 in the combination group, and immunofluorescence showed the greatest infiltration of CD8-positive cytotoxic T cells — the effector arm that can recognize tumor antigens and kill malignant cells throughout the body. Safety profiles were reassuring: treated mice maintained stable body weight, blood chemistry markers of liver and kidney function showed no significant deviations, and histology of major organs revealed no pathological changes or inflammatory infiltration.

The authors are candid about the work’s limits and its promise. They observed a degree of what they call synergistic overflow, in which the fully combined treatment did not always deliver benefit clearly beyond its individual components while adding preparation complexity, and they note that the tumor membrane itself may carry adjuvant properties that remain to be explored. They also point toward the clinic’s hardest problem: primary resistance to immune checkpoint inhibitors. By relieving hypoxia, inducing immunogenic cell death, activating cGAS–STING, and ferrying R848 into tumors to mature dendritic cells and recruit CD8-positive T cells, the platform could, in principle, convert immunologically cold tumors into hot ones and sensitize them to anti-PD-1 or anti-PD-L1 therapy — a hypothesis the team plans to test directly. For now, the study stands as a vivid demonstration that a nanoparticle wearing a tumor’s own face can carry an immune alarm clock deep into hostile territory, set it to go off under radiation, and leave the immune system to finish the job.

Subject of Research: A cancer-cell-membrane-coated MnO2 nanoplatform delivering the R848 adjuvant to enhance radio-immunotherapy of breast cancer

Article Title: Cancer-cell-mimicking MnO 2 nanoplatform delivers immunological adjuvants to enhance radio-immunotherapy

Article References: Zhang, Z., Liu, P., Zeng, W., Huang, C., Wang, S., Guan, S., Duan, Y., Wu, D., Zhao, Y., & Wu, J. (2026). Cancer-cell-mimicking MnO2 nanoplatform delivers immunological adjuvants to enhance radio-immunotherapy. Materials Today Bio, 41, Article 103720. https://doi.org/10.1016/j.mtbio.2026.103720

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103720

Keywords: MnO2 nanosheets, cancer cell membrane coating, R848, radio-immunotherapy, cGAS-STING pathway, immunogenic cell death, tumor hypoxia, dendritic cell maturation, CD8 T cells, breast cancer, biomimetic nanoparticles, drug delivery